|
General disorders and administration site conditions
|
|
Chest discomfort
|
3 (3.0)
|
0 (0.0)
|
|
Infections and infestations
|
|
Influenza
|
3 (2.0)
|
0 (0.0)
|
|
Nasopharyngitis
|
4 (2.6)
|
5 (3.3)
|
|
Rhinitis
|
3 (2.0)
|
1 (0.7)
|
|
Upper respiratory tract infection
|
4 (2.6)
|
9 (5.9)
|
|
Urinary tract infection
|
9 (5.9)
|
3 (2.0)
|
|
Investigations
|
|
Blood creatine phosphokinase increased
|
2 (1.3)
|
3 (2.0)
|
|
Blood glucose increased
|
1 (0.7)
|
3 (2.0)
|
|
Lipase increased
|
5 (3.3)
|
1 (0.7)
|
|
Metabolism and nutrition disorders
|
|
Hyperglycemia
|
3 (2.0)
|
6 (3.9)
|
|
Hypoglycemia
|
18 (11.8)
|
13 (8.5)
|
|
Musculoskeletal and connective tissue disorders
|
|
Arthralgia
|
3 (2.0)
|
3 (2.0)
|
|
Back pain
|
4 (2.6)
|
3 (2.0)
|
|
Nervous system disorders
|
|
Headache
|
0 (0.0)
|
3 (2.0)
|
